EpiPharm

Pre-clinical

Basel, SwitzerlandFounded 2017epipharm.ch

EpiPharm AG is a privately held, clinical-stage biotechnology company based in Switzerland, focused on the discovery and development of highly effective, natural treatments for skin disorders. The company's breakthrough platform centers on the therapeutic application of Artemisinin compounds, with a key publication validating artemether for seborrhoeic keratosis. Led by a highly experienced senior pharma executive team, EpiPharm holds therapeutic use patents until 2027/2034 and is actively pursuing partnership opportunities to advance its pipeline targeting dysplastic epidermal cell growth.

Founded

2017

Focus

Small Molecules

AI Company Overview

Technology Platform

Proprietary platform based on multi-active compositions of synergistically acting Artemisinin derivatives from Artemisia plants for the topical treatment and prevention of dysplastic epidermal cell growth.

Funding History

Total raised: $3.5M

Seed$3.5MHigh-Tech GründerfondsMay 15, 2021

Opportunities

The primary growth opportunity lies in partnering its late-stage seborrhoeic keratosis program to accelerate regulatory approval and commercialization.

Further opportunities exist in expanding the Artemisinin platform to other high-prevalence dermatological conditions like actinic keratosis, aesthetic pigment disorders, and potentially pre-cancerous lesion prevention, leveraging its novel natural mechanism.

Risk Factors

Key risks include dependency on securing partnership deals for funding and development, clinical trial failure in larger registrational studies, navigating complex regulatory pathways for natural compound combinations, and achieving market penetration against established procedural standards and potential new competitors in a crowded dermatology space.

Competitive Landscape

EpiPharm competes in the topical treatment space for benign skin lesions, primarily against procedural standards (cryotherapy) and limited pharmacological options. Its main differentiation is its novel, natural Artemisinin-based mechanism targeting dysplastic cell growth, which contrasts with synthetic single-mechanism drugs and offers a potential efficacy and safety advantage.